@inbook{5c7f326f94ff4a65a99bad7daf22aac4,
title = "Multimodality therapy for NSCLC",
abstract = "The standard therapy for patients with unrespectable stage III non-small-cell lung cancer (NSCLC) is the combination of chemotherapy and radiotherapy. Although the concurrent use of both treatment modalities has been shown to be superior to sequential therapy, the role for additional chemotherapy, either as induction or as consolidation, remains unclear. Targeted therapy has met limited success in the treatment of unselected patients with stage III NSCLC. New studies using induction therapy with erlotinib or crizotinib for molecularly selected patients and consolidation therapy with checkpoint inhibitors are currently ongoing, and the results are eagerly awaited.",
keywords = "Chemoradiotherapy, Immunotherapy, Molecularly targeted therapy, Stage III NSCLC",
author = "Lingling Du and Waqar, {Saiama N.} and Daniel Morgensztern",
year = "2016",
month = jan,
day = "1",
doi = "10.1007/978-3-319-40389-2_7",
language = "English",
series = "Cancer Treatment and Research",
publisher = "Kluwer Academic Publishers",
pages = "151--163",
booktitle = "Cancer Treatment and Research",
}